BMS sets up Roche, Pfizer rivalry with Turning Point takeover
pharmaphorum
JUNE 6, 2022
The results have set up a pre-filing meeting with the FDA, according to BMS. Rozlytrek was approved by the FDA in 2019 but has just started to gather sales momentum, making around $17 million in the first quarter of this year, an increase of 78% on the first three months of 2021.
Let's personalize your content